MXCT – maxcyte, inc. (US:NASDAQ)
Stock Stats
News
MaxCyte, Inc. (NASDAQ: MXCT) had its "overweight" rating re-affirmed by analysts at Stephens. They now have a $11.00 price target on the stock.
We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth [Yahoo! Finance]
MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024
Kytopen announces appointment of industry executive Kevin Gutshall as Chief Commercial Officer [Yahoo! Finance]
MaxCyte signs strategic platform license with Be Biopharma [Seeking Alpha]
Form ARS MAXCYTE, INC. For: Dec 31
Form DEF 14A MAXCYTE, INC. For: Jun 11
Form 4 MAXCYTE, INC. For: Mar 26 Filed by: Johnston John Joseph
Form SC 13G MAXCYTE, INC. Filed by: INTEGRATED CORE STRATEGIES (US) LLC
Form 4 MAXCYTE, INC. For: Mar 15 Filed by: Ross Thomas M.
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.